» Articles » PMID: 28888619

Natural Killer Cell-mediated Immunosurveillance of Human Cancer

Overview
Journal Semin Immunol
Date 2017 Sep 11
PMID 28888619
Citations 166
Authors
Affiliations
Soon will be listed here.
Abstract

The contribution of natural killer (NK) cells to immunosurveillance of human cancer remains debatable. Here, we discuss advances in several areas of human NK cell research, many of which support the ability of NK cells to prevent cancer development and avoid relapse following adoptive immunotherapy. We describe the molecular basis for NK cell recognition of human tumor cells and provide evidence for NK cell-mediated killing of human primary tumor cells ex vivo. Subsequently, we highlight studies demonstrating the ability of NK cells to migrate to, and reside in, the human tumor microenvironment where selection of tumor escape variants from NK cells can occur. Indirect evidence for NK cell immunosurveillance against human malignancies is provided by the reduced incidence of cancer in individuals with high levels of NK cell cytotoxicity, and the significant clinical responses observed following infusion of human NK cells into cancer patients. Finally, we describe studies showing enhanced tumor progression, or increased cancer incidence, in patients with inherited and acquired defects in cellular cytotoxicity. All these observations have in common that they, either indirectly or directly, suggest a role for NK cells in mediating immunosurveillance against human cancer. This opens up for exciting possibilities with respect to further exploring NK cells in settings of adoptive immunotherapy in human cancer.

Citing Articles

Efficacy Evaluation of "Enhanced" Natural Killers with and Knockouts on Viability and Metabolic Status of 3D Glioblastoma Spheroid Cells in Patients.

Yuzhakova D, Sachkova D, Shirmanova M, Shcheslavskiy V, Mozherov A, Dashinimaev E Sovrem Tekhnologii Med. 2025; 17(1):109-118.

PMID: 40071076 PMC: 11892565. DOI: 10.17691/stm2025.17.1.10.


Mendelian randomization study identifying immune cell phenotypes associated with breast cancer risk.

Zhang Z, Zhao J, Li Y, Zhang H, Chen Y, Yang L Discov Oncol. 2025; 16(1):205.

PMID: 39969618 PMC: 11839965. DOI: 10.1007/s12672-025-01963-z.


Pan-cancer and multi-omics analysis: NDUFA1 is a potential therapeutic target and prognostic marker for esophageal cancer.

Yin R, Zhou G, Liu G, Hou X, Yang H, Ge J Cell Biol Toxicol. 2025; 41(1):43.

PMID: 39937347 PMC: 11821742. DOI: 10.1007/s10565-025-09993-7.


Natural Killer Cells in Cancers of Respiratory System and Their Applications in Therapeutic Approaches.

Dokhanchi M, Javaherdehi A, Raad M, Khalilollah S, Mahdavi P, Razizadeh M Immun Inflamm Dis. 2024; 12(11):e70079.

PMID: 39588940 PMC: 11590036. DOI: 10.1002/iid3.70079.


Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities.

Bisht K, Merino A, Igarashi R, Gauthier L, Chiron M, Desjonqueres A Exp Hematol Oncol. 2024; 13(1):114.

PMID: 39538354 PMC: 11562869. DOI: 10.1186/s40164-024-00578-4.